Oxcarbazepine, an antiepileptic agent

Clinical Therapeutics

Volumn 23, Issue 5, 2001, Pages 680-700

  Kalis, Michelle M ^a   Huff, Nancy A ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Antiepileptic agents; Carbamazepine; Epilepsy; Oxcarbazepine

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450; DRUG METABOLITE; EPOXIDE; OXCARBAZEPINE; PLACEBO; SODIUM CHANNEL;

ARTICLE; CLINICAL TRIAL; DIPLOPIA; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; EPILEPSY; GRAND MAL EPILEPSY; HUMAN; HYPONATREMIA; MEDICAL INFORMATION; PLASMA PROTEIN BINDING; TREATMENT OUTCOME; VERTIGO;

EID: 0034998436     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80019-9     Document Type: Article

References (59)

1. 1. Hauser WA, Hesdorffer DC. Epilepsy: Frequency, Causes and Consequences. New York: Demos Publications; 1990.
2. 2. Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: An estimate from population-based clinical and survey data. Epilepsia. 2000; 41:342-351.
3. 3. Hauser WA. Seizure disorders: The changes with age. Epilepsia. 1992;33(Suppl 4):S6-S14.
4. 4. Grant SM, Faulds D. Oxcarbazepine: A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs. 1992;43:873-888.
5. 5. Elwes RDC, Binnie CD. Clinical pharmacokinetics of newer antiepileptic drugs. Clin Pharmacokinet. 1996;30:403-415.
6. 6. Beydoun A. Safety and efficacy of oxcarbazepine: Results of randomized, double-blind trials. Pharmacotherapy. 2000;20: S152-S158.
7. 7. Dam M, Ostergaard LH. Oxcarbazepine. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4th ed. New York: Raven Press; 1995:987-995.
8. 8. McLean MJ, Schmutz M, Wamil AW, et al, Oxcarbazepine: Mechanisms of action. Epilepsia. 1994;35(Suppl 3):S5-S9.
9. 9. Tecoma ES. Oxcarbazepine. Epilepsia. 1999;40(Suppl 5):S37-S46.
10. 10. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999;40(Suppl 5):S2-S10.
11. 11. Wamil AW, Portet CH, Jensen PK, et al. Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture. Epilepsia. 1991;32(Suppl 3):65-66. Abstract.
12. 12. Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11 dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem. 1999;42:2582-2587.
13. 13. Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels: Targets of antiepileptic drug therapy? Epilepsia. 1997;38:959-965.
14. 14. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1995;36(Suppl 2):S2-S12.
15. 15. Kalviainen R, Keranen T, Riekkinen PJ. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs. 1993;46: 1009-1024.
16. 16. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia. 1999;40(Suppl 9):S7-S13.
17. 17. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol. 1989;37:69-74.
18. 18. Trileptal tablets (Physicians' Desk Reference®). In: Drugdex System. Englewood, Colo: Micromedix, Inc: 2000. Accessed November 1, 2000.
19. 19. Winter M. Clinical pharmacokinetics. In: Young LY, Koda-Kimble MA, eds. Applied Therapeutics: The Clinical Use of Drugs. 6th ed. Vancouver, Wash: Applied Therapeutics Inc; 1995:1-19.
20. 20. Kumps A, Wurth C. Oxcarbazepine disposition: Preliminary observations in patients. Biopharm Drug Dispos. 1990;11: 365-370.
21. 21. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 1993;87:224-227.
22. 22. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: Reexamining its role in the treatment of epilepsy. Epilepsia. 2000;41(Suppl 8):S6-S15.
23. 23. Volosov A, Xiaodong S, Perucca E, et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther. 1999;66: 547-553.
24. 24. Cloyd JC, Remmel RP. Antiepileptic drug pharmacokinetics and interactions: Impact on treatment of epilepsy. Pharmacotherapy. 2000;20:S139-S151.
25. 25. Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet. 1996; 31:309-324.
26. 26. van Heiningen PNM, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther. 1991;50:410-419.
27. 27. Tomson T, Johanessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol. 2000;55:697-705.
28. 28. Houtkooper MA, Lammertsma A, Meyer JWA, et al. Oxcarbazepine (GP 47.680): A possible alternative to carbamazepine? Epilepsia. 1987;28:693-698.
29. 29. Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 1999;52: 732-737.
30. 30. Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures. Neurology. 2000; 54:2245-2251.
31. 31. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597-1607.
32. 32. Glauser TA, Nigro M, Sachdeo R, et al, for the Oxcarbazepine Pediatric Study Group. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology. 2000;54:2237-2244.
33. 33. Gaily E, Granstrom M-L, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol. 1997; 12:496-498.
34. 34. Gareri P, Gravina T, Ferreri G, de Sarro G. Treatment of epilepsy in the elderly. Prog Neurobiol. 1999;58:389-407.
35. 35. Cheshire WP. Trigeminal neuralgia: A guide to drug choice. CNS Drugs. 1997;7: 98-110.
36. 36. Dunn RT, Frye MS, Kimbrell TA, et al. The efficacy and use of anticonvulsants in mood disorders. Clin Neuropharmacol. 1998;21:215-235.
37. 37. Lindstrom P. The analgesic effect of carbamazepine in trigeminal neuralgia. Pain. 1987;28(Suppl 4):S85. Abstract.
38. 38. Post RM, Ketter TA, Denicoff K, et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology. 1996;128:115-129.
39. 39. Windhaber J, Maierhofer D, Dantendorfer K. Oxcarbazepine for panic disorder occurring after two grand mal seizures: A case report. J Clin Psychiatry. 1997;58: 404-405.
40. 40. Beydoun A. Monotherapy trials of new antiepileptic drugs. Epilepsia. 1997;38 (Suppl 9):S21-S31.
41. 41. Sillanpaa M. Carbamazepine. Pharmacology and clinical uses. Acta Neurol Scand Suppl. 1981;88:145-150.
42. 42. Pendlebury SC, Moses DK, Eadie MJ. Hyponatraemia during oxcarbazepine therapy. Hum Toxicol. 1989;8:337-344.
43. 43. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review, Epilepsia. 1994;35:181-188.
44. 44. Steinhoff BJ, Stoll K-D, Stodieck SRG, Paulus W. Hyponatremic coma under oxcarbazepine therapy. Epilepsy Res. 1992; 11:67-70.
45. 45. Bulau P, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol. 1988;34:311-313.
46. 46. Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989;3: 70-76.
47. 47. Gatzonis SD, Georgaculias N, Singounas E, et al. Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation, Neurology. 1999;52: 1918-1919.
48. 48. May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: Results of a retrospective study. Ther Drug Monit. 1999;21:175-181.
49. 49. McKee PJW, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol. 1994;37:27-32.
50. 50. Tartara A, Galimberti CA, Manni R, et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxycarbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol. 1993;36:366-368.
51. 51. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia. 1999;40:783-787.
52. 52. Zaccara G, Gangemi RF, Bendoni L, et al. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit. 1993;15:39-42.
53. 53. Keranen T, Jolkkonen J, Jensen PK, et al. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand. 1992;86:120-123.
54. 54. Keranen T, Jolkkonen J, Klosterskov-Jensen PK, Menge GP. Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurol Scand. 1992;85:239-242.
55. 55. Kramer G, Tettenborn B, Flesch G. Oxcarbazepine-verapamil drug interaction in healthy volunteers. Epilepsia. 1991;32 (Suppl 1):70-71. Abstract.
56. 56. Kramer G, Tettenborn B, Klosterskov-Jensen P, et al. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia. 1992;33:1145-1148.
57. 57. Brodie MJ. Monostars: An aid to choosing an antiepileptic drug as monotherapy. Epilepsia. 1999;40(Suppl 6):S17-S22.
58. 58. Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. Drugs. 1999;57: 535-544.
59. 59. Jung H, Noguez A, Mayet L, et al. The distribution of 10-hydroxy carbazepine in blood compartments. Biopharm Drug Dispos. 1997;18:17-23.